期刊文献+

影响心脑血管疾病患者他汀药物治疗依从性相关因素Logistic回归分析 被引量:2

Logistic Regression Analysis of Factors Related to Statin Drug Compliance in Patients with Cardiovascular and Cerebrovascular Diseases
下载PDF
导出
摘要 目的探讨影响心脑血管疾病患者他汀药物治疗依从性的相关因素。方法 2016年1月—2017年6月该院用他汀药物治疗心脑血管疾病患者120例,比较不同依从性心脑血管疾病患者相关因素上的差异。结果 120例心脑血管疾病患者应用他汀药物依从性好64例,占总数的60.00%(72/120),依从性差48例,占总数的40.00%(48/120);单因素8个方面差异有统计学意义(χ~2=6.68、7.04、6.69,4.03、7.06,8.16、6.56、9.15、4.26,P<0.05);Logistic回归分析影响心脑血管疾病他汀药物治疗依从性独因素:心脑血管疾病及他汀药物认知匮乏(OR=4.237,95%CI:1.229,15.382)、年龄≥60岁(OR=3.643,95%CI:1.325,12.472)、他汀药物不良反应较重(OR=3.387,95%CI:1.103,14.093)、病情严重(OR=2.774,95%CI:1.026,11.237)。结论心脑血管疾病患者他汀药物过程中心脑血管疾病及他汀药物认知、年龄、他汀药物不良反应及病情严重程度影响了依从性,应实施相应的措施提高他汀药物依从性。 Objective To investigate the related factors affecting the compliance of statin therapy in patients with cardiovascular and cerebrovascular diseases. Methods From January 2016 to June 2017, 120 patients with cardiovascular and cerebrovascular diseases were treated with statin drugs in the hospital. The differences in related factors between patients with different cardiovascular and cerebrovascular diseases were compared. Results In 120 patients with cardiovascular and cerebrovascular diseases, 64 patients with statin compliance were good, accounting for 60.00% (72/120) of the total, 48 patients with poor compliance, accounting for 40.00% (48/120) of the total; ,the difference was statistically signficant(χ^2=6.68, 7.04, 6.69, 4.03, 7.06, 8.16, 6.56, 9.15, 4.26, P〈0.05); Logistic regression analysis of cardiovascular and cerebrovascular diseases statin drug treatment compliance alone factors: cardiovascular and cerebrovascular diseases and statin recognition knowledge deficit (OR=4.237, 95% CI:1.229,15.382), age ≥ 60 years (OR=3.643, 95% CI:1.325,12.472), statin drug side effects are heavier (OR=3.387, 95% CI:1.103,14.093), the condition is serious (OR =2.774, 95% CI:1.026,11.237). Conclusion Cerebrovascular disease patients with cerebral vascular disease and statin cognition, age, statin side effects and severity of the disease affect compliance, and corresponding measures should be implemented to improve statin compliance.
作者 王平 WANG Ping(Department of Internal Medicine,Nantong Maternal and Child Health Hospital,Nantong,Jiangsu Province,226010 China)
出处 《系统医学》 2018年第17期70-72,共3页 Systems Medicine
关键词 心脑血管疾病 他汀药物 依从性 影响因素 Cardiovascular and cerebrovascular diseases Statin drugs Compliance Influencing factors
  • 相关文献

参考文献12

二级参考文献113

  • 1Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism [J]. Am J Cardiovasc Drugs, 2008,8 (6) : 373-418. 被引量:1
  • 2Schech S,Graham D,Staffa J,et al. Risk factors for statin-associated rhabdomyolysis[J].Pharmacoepidemiol Drug Saf,2007,16 (3): 352-358. 被引量:1
  • 3Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins[J].Drugs Aging, 2007,24(5 ): 429-440. 被引量:1
  • 4Card JW, Racz WJ, Brien JF, et al. Attenuation of amiodarone- induced pulmonary fibrosis by vitamin e is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction [J]. J Pharmacol Exp Ther, 2003,304( 1 ) : 277-283,. 被引量:1
  • 5Chapplain JM, Beillot J, Begue JM, et al. Mitochondrial abnormalities in hiv-infected lipoatrophic patients treated with antiretroviral agents [ J ]. J Acquir Immune Defic Syndr, 2004,37 (4): 1477-1488. 被引量:1
  • 6Neuvonen PJ,Niemi M,Backman JT. Drug interactions with lipidlowering drugs : Mechanisms and clinical relevance [J]. Clin Pharmacol Ther, 2006,80( 6 ) : 565-581. 被引量:1
  • 7Abbott A. With your genes? Take one of these,three times a day [J]. Nature, 2003,425 (6956) : 760-762. 被引量:1
  • 8Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation [J].Pharmacotherapy, 2008,28 (9) : 1188-1193. 被引量:1
  • 9Yoon HE,Song JC,Hyoung BJ,et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients [ J ]. Korean J Intern Med, 2009, 24(3): 233-237. 被引量:1
  • 10Guyton JR,Brown BG,Fazio S,et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type Ⅱ a or type lIb hyperlipidemia [J]. J Am Coll Cardiol, 2008,51 (16) : 1564-1572. 被引量:1

共引文献147

同被引文献12

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部